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Abstract
Background: Pancreatic ductal adenocarcinoma (PDA) is comprised of a prominent desmoplastic
stromal compartment and only 10–40% of the tumour consists of PDA cells. However, how stromal
components should be assessed and how the characteristics of the stromal compartment determine
clinical outcomes in PDA patients remain unknown.
Method: A cohort of 66 consecutive patients who underwent pancreaticoduodenectomy and were
primarily followed at Johns Hopkins Hospital between 1998 and 2004, and treated with adjuvant therapy,
were included in a retrospective analysis. Resected PDA blocks with good tissue preservation were
available for all patients. A new, computer-aided, quantitative method was developed to assess the
density and activity of stroma in PDAs and the associations of these characteristics with clinical
outcomes.
Results: High stromal density in resected PDA was found to be significantly associated with longer
disease-free [adjusted hazard ratio (aHR) 0.39; P = 0.001] and overall (aHR 0.44; P = 0.004) survival after
adjusting for the use of pancreatic cancer vaccine therapy, as well as gender and resection margin
positivity. Stromal activity, representing activated pancreatic stellate cells in PDAs, was not significantly
associated with the prognosis of resected PDAs.
Conclusions: These results illustrate the complexity of the role of stroma in PDAs. Further exploration
of the prognostic ability of the characteristics of stroma is warranted.
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Introduction
Pancreatic ductal adenocarcinoma (PDA) is currently the 10th
leading cause of cancer in the USA. However, its associated mor-
tality is disproportionally high as PDA is the country’s fourth
leading cause of cancer-related death.1 The overall poor prognosis
has been attributed to both late detection, typically at a relatively
advanced stage, and the lack of effective treatments.2
Pancreatic ductal adenocarcinoma cells constitute only 10–40%
of PDA tumour volume and are surrounded by a dense, collagen-
ous, hypovascular, desmoplastic stromal compartment. This
stroma is composed of extracellular matrix proteins, fibroblasts,
stellate cells and inflammatory cells. Pancreatic stellate cells
(PSCs) in their activated form produce extracellular matrix com-
ponents, lose their vitamin A storage capacity, and have enhanced
α-smooth muscle actin (α-SMA) expression.3–5 In turn, PSCs have
been shown to promote tumorigenesis and chemoresistance in
vitro.3–5 Emerging evidence suggests that the depletion of tumour-
associated stromal fibroblasts by disrupting Hedgehog signalling,
the ablation of hyaluronic acid from the extracellular matrix by
pegylated recombinant hyaluronidase, and the depletion of
stromal fibroblasts expressing fibroblast activation protein-α
(FAP-α) in mouse models of PDA result in improved delivery
and greater antitumour activity of chemotherapy agents or*These authors contributed equally to this paper.
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immune-mediated hypoxic necrosis of the tumour. These results
indicate that the stromal compartment may play a determinant
role in the prognosis of PDA.6–8
The present paper reports the development of a new, computer-
aided, quantitative method to assess the density and activity of
stroma in PDAs and their association with clinical outcomes. High
stromal density, but not SMA expression, represented by stromal
activity, in resected PDA was found to be significantly associated
with longer disease-free survival (DFS) and overall survival (OS).
Materials and methods
Patients and specimens
This retrospective study refers to data for consecutive patients
submitted to pancreaticoduodenectomy between 1998 and 2004
at Johns Hopkins Hospital (JHH) and subsequently treated with
adjuvant chemoradiation therapy. Only patients primarily fol-
lowed at JHH were included. The study inclusion criteria also
required the existence of archived paraffin-embedded tissue
blocks with good tissue preservation. A total of 66 patients were
eligible for analysis. Among them, 38 patients participated in an
adjuvant pancreatic cancer vaccine study and received an
allogeneic granulocyte-macrophage colony-stimulating factor
(GM-CSF)-secreting whole-cell pancreatic cancer vaccine
(GVAX) in addition to standard chemotherapy and radiation.9
None of the 66 patients were treated with neoadjuvant therapy.
Immunohistochemistry
In this study, a novel method for the quantification of tumour
stroma was employed, in which tumours were co-stained for epi-
thelial tumour cells and stromal collagen and then quantified
using computer-based image analysis. Sections of formalin-fixed,
paraffin-embedded tissue of 3 μm in thickness were stained for
pankeratin [anti-pankeratin (AE1/AE3/PCK26), 1:100; Ventana
Medical Systems, Inc., Tucson, AZ, USA] using a Dako autostainer
(Dako, Agilent Technologies, Santa Clara, CA, USA) with a high
pH retrieval and 3,3′-diaminobenzidine detection, and using a
modified protocol in which counterstaining with haematoxylin
was not performed prior to fixing in Bouin’s 2000 overnight at
room temperature and subsequent counterstaining with aniline
blue. Staining for α-SMA on consecutive sections of the same
blocks was performed at the JHH Immunopathology Laboratory
using a Ventana autostainer with mouse anti-SMA immuno-
globulin G (IgG) antibody (clone: 1A4; catalogue no. 760–2833;
Ventana Medical Systems, Inc.) according to the manufacturer’s
protocols, with 3,3′-diaminobenzidine detection and
haematoxylin counterstaining.
Image analysis
All slides were scanned and images analysed using ImageScope
Viewer (Aperio Technologies, Inc., Vista, CA, USA). The area of
tumour to be analysed was circled by a blinded pathologist (RAA)
on haematoxylin and eosin-stained slides in such a way as to
include the largest area possible of continuous neoplastic tissue
and to exclude, as far as possible, normal pancreatic, intestinal and
muscle tissue. The positive pixel count algorithm was used to
count positive (brown) and negative (blue) pixels in the specified
area. The stromal density, defined by the ratio of the area of
stroma to that of the total tumour mass, was calculated as the total
number of negative (blue, staining for collagen) pixels divided by
the total number of pixels [blue (staining for collagen) plus brown
(staining for pankeratin)] in the selected tumoral area in slides
stained for pankeratin and collagen. Similarly, slides stained for
SMA were scanned and positive (brown, staining for smooth-
muscle actin) and negative (blue, staining for nuclei) pixels in the
predefined tumoral area were counted. As most stromal cells
express SMA at a certain level, whereas PSC is characterized by a
high level of SMA expression, stromal activity was defined as the
percentage of stromal cells demonstrating the strong expression of
SMA among all cells expressing SMA and scored as the total
number of strongly positive pixels divided by the total number of
positive pixels in the selected area. The default threshold of 100
was used to select strongly positive pixels as per the software user’s
guide. The expression of SMA in a randomly selected area of
smooth muscle was used to normalize the variation in staining
between slides from different batches of staining.
Statistical analysis
Comparisons of the clinical and pathological characteristics of the
two cohorts were made using Fisher’s exact test and the Wilcoxon
rank-sum test. Disease-free survival was defined as the time from
surgery to the first evidence of local or metastatic recurrent
disease or death from any cause. Overall survival was defined as
the time from surgery to death from any cause. Individuals were
censored for DFS or OS at the date of the last known scan or
contact, respectively, if no events were observed. Kaplan–Meier
estimates of the survival function were used to graphically
compare the time-to-event outcomes based upon treatment, as
well as stromal characteristics. Comparisons between groups
were made with log-rank tests and Cox proportional hazards
regression models. All analyses were performed using R: A Lan-
guage and Environment for Statistical Computing (http://www.R-
project.org; R Foundation for Statistical Computing, Vienna,
Austria).
Results
A total of 66 patients submitted to pancreaticoduodenecotmy
followed by adjuvant chemoradiation, who were primarily fol-
lowed at JHH, and for whom well-preserved tissue blocks were
available, were identified and included in the retrospective analysis
(Table 1 and Table S1, online). Pankeratin staining in combina-
tion with collagen staining was performed on these tissue speci-
mens and used to quantify stromal density (Fig. 1a, b). Median OS
was 22.2 months [95% confidence interval (CI) 17.7–26.3] in the
entire cohort, 25.1 months (95% CI 21.7–41.4) in individuals with
high stromal density (≥0.8), and 14.4 months (95% CI 11.1–24.2)
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in individuals with low stromal density (<0.8) (Fig. 2a). In unad-
justed analyses, high stromal density was associated with signifi-
cantly longer OS than low stromal density [unadjusted hazard
ratio (uHR) 0.43, 95% CI 0.24–0.74; P < 0.001]. Median DFS was
14.8 months (95% CI 10.5–18.8) in the entire cohort, 18.7 months
(95% CI 14.7–30.8) in individuals with high stromal density,
and 9.6 months (95% CI 7.3–17.0) in those with low stromal
density (Fig. 2b). Individuals with high stromal density remained
disease-free for significantly longer than those with low-
density stroma (uHR 0.44, 95% CI 0.25–0.77; P = 0.003). Gender,
tumour volume, tumour grade and type of adjuvant therapy
(chemoradiation alone or with GVAX) were not significantly asso-
ciated with OS. The association between positive resection margin
status and shorter OS was of borderline significance (uHR 1.60;
P = 0.08), as anticipated (Table S1). These results suggest that high
stromal density appears to be a good prognostic factor for PDAs
following pancreaticoduodenectomy and adjuvant therapy.
As preclinical studies have suggested that stroma promotes PDA
growth and metastasis, it is not anticipated that high stromal
density would be associated with a better prognosis. Thirty-eight
(58%) of the 66 patients were treated with GVAX, which was
developed through a clinical trial in the adjuvant setting, in addi-
tion to standard chemoradiation (Table S1). There was no signifi-
cant difference between the vaccinated patient group and the
unvaccinated patient group in terms of age, gender, node positiv-
ity, tumour grade or the proportion of patients with a tumour size
of ≥3 cm. This raised the question of whether it was possible that
the inclusion of these 38 vaccinated patients may have changed the
prognostic value of stromal density. It should be noted that the
effects of gender on OS and DFS differed between the vaccinated
patient group and the group of patients treated with adjuvant
chemoradiation only (test of interaction: P = 0.008 and P < 0.001,
respectively). In the vaccinated group, there was no significant
difference in OS and DFS between men and women; however,
among individuals receiving adjuvant chemoradiation therapy
only, men had significantly longer OS and DFS than women
(Tables 2 and 3). Therefore, the analysis was adjusted for gender,
margin status and the receipt of vaccine treatment to explore the
potential influence of the vaccine. Nonetheless, the association of
high stromal density with longer OS remained significant after
simultaneously adjusting for the receipt of vaccine treatment as
well as for gender and margin status. The effect of stromal density
was virtually unchanged (aHR 0.44, 95% CI 0.25–0.77; P = 0.004)
(Table 2), whereas the risk increased slightly for margin-positive
individuals and became statistically significant (aHR 1.97, 95% CI
1.08–3.58; P = 0.027). Similarly to observations for OS, the asso-
ciation of high stromal density with longer DFS persisted (aHR
0.39, 95% CI 0.21–0.70; P = 0.001) after adjusting for the use of
vaccine therapy, as well as gender and margin positivity.
Next, SMA expression, designated stromal activity, which is a
surrogate marker of activated PSCs, was examined (Fig. 1c–f).
Stromal activity was not significantly associated with OS (HR
0.85, 95% CI 0.54–1.35; P = 0.49 comparing stromal activity of
≥1.46 versus <1.46) or DFS (HR 0.79, 95% CI 0.49–1.27; P = 0.33).
Stromal activity was similar across the vaccinated patient group
and the unvaccinated patient group (1.51 versus 1.50; P = 0.20).
Therefore, immunohistochemical assessment of SMA expression
may not have a prognostic value in resected PDA.
Discussion
The present report has described a new method of quantifying
stromal density and stromal activity in resected PDAs. Using this
method, the current study has demonstrated the prognostic value
of stromal density in patients submitted to the surgical resection
of PDAs followed by adjuvant chemoradiation with or without the
GM-CSF-secreting pancreatic cancer vaccine treatment.
Although the desmoplastic component of pancreatic adenocar-
cinoma has long been appreciated, until recently its role in
tumorigenesis was poorly understood. There is now increasing
evidence that the tumour stroma is a dynamic compartment that
may promote tumorigenesis.3–5 However, this has been difficult to
Table 1 Clinical and pathological characteristics of patients
Characteristic Overall (n = 66) Unvaccinated
patients (n = 28)
Vaccinated
patients (n = 38)
P-value
Age at surgery, years, median (range) 63 (43–83) 63 (44–80) 62 (43–83) 0.690
Female, n (%) 28 (42%) 11 (39%) 17 (45%) 0.800
Node-positive, n (%) 62 (94%) 27 (96%) 35 (92%) 0.630
Margin-positive, n (%) 31 (47%) 17 (61%) 14 (37%) 0.081
Tumour characteristics
Size, cm, median (range) 3.0 (1.0–6.0) 3.0 (1.0–5.5) 3.0 (1.3–6.0) 0.220
≥3 cm, n (%) 38 (58%) 18 (64%) 20 (53%) 0.450
Tumour grade 3–4, n (%) 24 (36%) 11 (39%) 13 (34%) 0.800
Stroma characteristics
Stromal density, median (range) 0.83 (0.46–0.98) 0.83 (0.46–0.92) 0.83 (0.54–0.98) 0.440
Stromal activity, median (range) 1.51 (0.16–9.72) 1.50 (0.21–9.72) 1.51 (0.16–5.04) 0.200
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validate clinically. This study employed a novel method of quan-
tifying stroma in clinical samples, in which the amounts of both
collagen and tumour were directly measured. Using this measure,
high stromal density was significantly associated with improved
survival. By contrast, stromal activity does not appear to have
prognostic value. Although these results are unexpected, they
illustrate the complexity of the role of the stroma in PDAs. The
quantity of stroma or the extent of desmoplasia itself is not nec-
essarily associated with the aggressiveness of PDA. On the con-
trary, it is strongly associated with a better prognosis. In addition,
SMA expression is also not prognostic. One possible explanation
is that PDA growth is proinflammatory and thus slow-growing
PDAs accumulate more fibrotic stroma as a result of the longer
duration of inflammatory response. Another possibility is that
PDAs with favourable outcomes are associated with an
immunoactive tumour microenvironment that results in a high
stromal density, whereas those with unfavourable outcomes are
associated with an immunosuppressive tumour microenviron-
ment that results in a low stromal density. A third possibility is
that high stromal density has selected more preferentially the infil-
tration of antitumour effector immune cells or less preferentially
the infiltration of pro-cancerous immunosuppressive cells.
However, no association between stromal density or activity and
CD8+ or Foxp3+ cells was observed, which suggests that the
mechanisms, if they exist, are more complex than a single marker
will demonstrate. This hypothesis is consistent with recently
(a) (b)
(d)(c)
(f)(e)
Figure 1 Immunohistochemistry staining and quantification of stromal density and activity in pancreatic ductal adenocarcinoma (PDA). (a)
Representative immunohistochemistry staining of pankeratin (brown signals) and collagens (blue signals). (b) Representative quantification
of stromal density in the intratumoral area (enclosed). (c) Representative immunohistochemistry staining of smooth muscle actin (SMA)
(brown signals). (d) Representative quantification of stromal activity in the intratumoral area (enclosed). (e) Representative PDA with high
stromal activity/strong SMA expression. (f) Representative PDA with low stromal activity/weak SMA expression
HPB 2015, 17, 292–298
HPB 295
© 2014 International Hepato-Pancreato-Biliary Association
published studies showing that the depletion of stroma in the
mouse model of PDA facilitates tumour growth and metasta-
sis.10,11 One of these published studies suggests that stroma-rich
PDAs are associated with differentiated histology, whereas
stroma-poor PDAs are associated with less differentiated histol-
ogy,11 and provides a potential mechanistic explanation for the
present results. Thus, further exploration of the mechanisms
underlying the prognostic value of the stroma is warranted. The
present study and these recently published studies have suggested
that an effective antitumour treatment should target a specific
stromal component rather than targeting the stroma in general.
Several ongoing clinical trials are investigating the targeting of
the stroma as a new therapeutic strategy in patients with pancre-
atic cancer and have shown conflicting results, some of which have
been promising (Phase I hyaluronidase study), although others
have been disappointing (Hedgehog inhibitor IPI926 Phase II
study).12,13 The contradictions among the findings of different
preclinical studies and between the findings of preclinical studies
and the outcomes of clinical trials highlight the need to better
elucidate the mechanistic roles of stromal components in
tumorigenesis, antitumour immune response, and drug resist-
ance.14,15 The present method of quantifying the stromal compart-
ment may have utility in ongoing trials that have collected
pre- and post-treatment human specimens to further investigate
the effects of these therapies.
The present study is limited by its small sample size and retro-
spective nature. An unexpected result of this study refers to the
significantly different influences of gender on clinical outcomes in
those treated with and without vaccine; however, the sample size
was quite small and the results require to be validated in a future
study. The aetiology of this gender effect is unknown, although
previous studies have hinted at the possibility of such an effect.16
1.0
(a)
(b)
0.8
0.6
0.4
P
er
ce
nt
ag
e 
al
iv
e
0.2
0.0
0 10 20 30
Time, months
40 50 60
26 20 9 4 2 1 1
40
Stromal density < 0.8:
Stromal density ≥ 0.8: 38 25 16 11 9 6
< 0.8
Stromal density
≥ 0.8
1.0
0.8
0.6
0.4
P
er
ce
nt
ag
e 
di
se
as
e-
fr
ee
0.2
0.0
0 10 20 30
Time, months
40 50 60
26 10 3 2 2 1 1
40
Stromal density < 0.8:
Stromal density ≥ 0.8: 32 17 13 8 6 3
< 0.8
Stromal density
≥ 0.8
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After adjusting for potential confounders including gender and
treatment, stromal density remained significantly associated with
clinical outcome. Given the simplicity of the method for measur-
ing stromal density presented in this study, stromal density can be
further explored for its prognostic value in PDAs and in other
solid malignancies, as well as for its predictive value in selecting
patients who may respond to novel stroma-targeting therapies.
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